Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19.
Angiogenesis
; 24(1): 13-15, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-866224
ABSTRACT
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal-dominant disease characterized by pathologic angiogenesis that provokes vascular overgrowth. The evidence about the influence of Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in patients with rare diseases is scarce. We aimed to know the prevalence of coronavirus disease 2019 (COVID-19) in HHT patients. The HHT pathogenic angiogenesis and endothelial injury in COVID-19 are discussed using data from RiHHTa (Computerized Registry of Hereditary Hemorrhagic Telangiectasia) registry. RiHHTa is an open, multicenter, prospective, observational registry including adult patients with HHT. A 27-item survey that captured clinical data of admitted HHT patients for COVID-19 was distributed to all RiHHTa investigators from June 8th to June 24th 2020. Only one out of 1177 HHT patients was admitted for COVID-19 pneumonia. She is a 74 years-old woman with a pathogenic variant in ACVRL1 gene. Her clinical course did not involve mechanical ventilation or worsening epistaxis, and she was successfully discharged after two weeks. The endothelial damage and the consequent angiogenic process in COVID-19 patients deserve further investigation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Telangiectasia, Hereditary Hemorrhagic
/
Activin Receptors, Type II
/
COVID-19
/
Neovascularization, Pathologic
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
/
Variants
Limits:
Aged
/
Female
/
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Angiogenesis
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
S10456-020-09755-5
Similar
MEDLINE
...
LILACS
LIS